ReviewWorld journal of gastroenterology2013
Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects.
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.Mucosal immunology · 2018Trial
- Integrated omics revealed the altered colonic microenvironment after inhibition of peripheral serotonin synthesis by LP533401.iMetaOmics · 2024Article
- Review
- Investigation of Microbial Translocation,Cancers · 2022Article
- The Relation Between Host TLR9 -1486T/C, rs187084 Gene Polymorphisms andPolish journal of microbiology · 2022Article
- Progress of Phototherapy Applications in the Treatment of Bone Cancer.International journal of molecular sciences · 2021Review
- Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility.BioMed research international · 2021Review
- The mitochondrial negative regulator MCJ modulates the interplay between microbiota and the host during ulcerative colitis.Scientific reports · 2020Article
- Toll-like receptor 9 polymorphisms andWorld journal of gastrointestinal oncology · 2019Article
- Ingestion of Non-digestible Carbohydrates From Plant-Source Foods and Decreased Risk of Colorectal Cancer: A Review on the Biological Effects and the Mechanisms of Action.Frontiers in nutrition · 2019Review
- Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer.Oncology letters · 2017Article
- Nucleic acid sensing pattern recognition receptors in the development of colorectal cancer and colitis.Cellular and molecular life sciences : CMLS · 2017Review
- Role of intestinal microbiota and metabolites on gut homeostasis and human diseases.BMC immunology · 2017Review
- Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Translational research : the journal of laboratory and clinical medicine · 2016Review
- Association of Single Nucleotide Polymorphisms in Toll-like Receptors with Acinetobacter baumanii Infectionin a Chinese Population.Iranian journal of public health · 2016Article
- 1,25-hydroxyvitamin D relieves colitis in rats via down-regulation of toll-like receptor 9 expression.Croatian medical journal · 2015Article
- Selective induction of apoptosis in human gastric cancer cells by Lactobacillus kefiri (PFT), a novel kefir product.Oncology reports · 2015Article
- Involvement of Visceral Adipose Tissue in Immunological Modulation of Inflammatory Cascade in Preeclampsia.Mediators of inflammation · 2015Article
- Cell Free DNA of Tumor Origin Induces a 'Metastatic' Expression Profile in HT-29 Cancer Cell Line.PloS one · 2015Article
- Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptors (TLRs) recognize specific motifs which are frequently present in bacteria, fungi, prokaryotes and viruses. Amongst TLRs, TLR9 can be activated by such bacterial or viral DNA fragments, immunoglobulin-DNA complexes or synthetic oligonucleotides, which all contain unmethylated cytosine-guanine nucleotide sequences (CpGs). Emerging data indicate that TLR9 signaling has a role in, and may influence, colorectal carcinogenesis and colonic inflammation. CpGs are classified into three groups according to their influence on both the antigen-specific humoral- and cellular immunity, and the production of type 1 interferons and proinflammatory cytokines. TLR9 activation via CpGs may serve as a new therapeutic target for several cancerous and various inflammatory conditions. Due to its probable anti-cancer effects, the application possibilities of TLR9-signaling modulation may be extremely diverse even in colorectal tumors. In this review we aimed to summarize the current knowledge about TLR-signaling in the pathogenesis and therapy of inflammatory bowel diseases and colorectal cancer. Due to the species-specific differences in TLR9 expression, however, one must be careful in translating the animal model data into the human system, because of the differences between CpG-oligodeoxynucleotide-responsive cells. TLR9 agonist DNA-based immunomodulatory sequences could also represent a promising therapeutic alternative in systemic inflammatory conditions and chronic colonic inflammations as their side effects are not significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.